Top Agentic AI Use Cases in Pharma (2026)

Three tiers of “real”, and why the distinction is load-bearing

Agentic AI claims in pharmaceuticals fall into three tiers. Tier one is shipped: a named vendor made a named capability generally available on a stated date, and you can license it. Tier two is piloted: a named organisation is running it, usually in limited geographies, with results sometimes reported. Tier three is described: the use case is plausible, the architecture is drawable, and nobody has published a deployment. All three appear in vendor material using the same confident language, and separating them is the single most useful thing a buyer can do before building a roadmap.
 

A practical rule for reading anything in this category, including this article: if a claim has no date, no named organisation and no geography, it belongs in tier three regardless of how confidently it is stated. Applying that filter to a typical agentic AI vendor deck usually removes most of it, and what remains is a much more useful document.

Real examples of agentic AI in pharma commercial

Commercial is the function with the deepest shipped tier, and it is largely absent from independent surveys of agentic AI in pharma. Veeva made AI agents generally available inside Vault CRM and PromoMats on 3 December 2025, including Voice, Pre-call and Free Text agents and content agents for promotional review. Salesforce Agentforce Life Sciences reached general availability on 11 October 2025 and by June 2026 Salesforce reported 140 life sciences clients. IQVIA launched IQVIA.ai, a unified agentic platform built with NVIDIA, on 16 March 2026. These are purchasable today, which is a different proposition from most of what is written about agentic AI in this industry.

Two observations a chief commercial officer should take from that table. First, the shipped tier in commercial is not thin — it is the deepest in the industry, and every entry is dated and licensable. Second, the FDA row is the one to raise internally, because a regulator deploying agentic AI across premarket review and inspection functions changes the conversation about whether this technology is credible in a regulated environment. It is difficult to argue that agents are too immature for commercial operations while the agency reviewing your submissions is using them.

Across the value chain: what is actually where

Outside commercial, maturity varies sharply by function. Manufacturing deviation investigation is the most production-like use case, with reported cycle-time reductions of 40–50%. Research and clinical development are largely proof of concept, with credible administrative gains — one startup reports roughly 50% faster administrative trial tasks, and a literature-review deployment reports around 60% time reduction — but no autonomous clinical decision-making. Regulatory submission assembly and pharmacovigilance case intake are in development. Supply chain remains speculative.

There is a pattern worth naming. Every use case that has reached production or credible pilot status shares three properties: the task is administrative rather than clinical, the output is reviewed by a human before it has consequence, and the work was previously done by people following a documented process. Deviation investigation, medical writing first drafts, call reporting, literature review — all administrative, all reviewable, all previously proceduralised. The use cases still described rather than deployed tend to violate at least one of those conditions.

The adoption numbers, and what they are telling you

The headline statistics in this category are contradictory only if you read them carelessly. Around 80% of enterprise applications embed at least one AI agent, because vendors have added agentic features to products organisations already own. Around 31% of enterprises run an agent in production, because operating one requires data, governance and process change that embedding does not. Gartner forecasts that more than 40% of agentic AI projects will be cancelled by the end of 2027. The single most cited blocker is not model capability — 52% of enterprises name poor data quality.

The data quality figure is the one to sit with, because it points somewhere specific. An agent is a system that takes action on the basis of what it believes to be true. If your customer master carries a high duplication rate — the discrepancy rate we observe in pharma CRM doctor records runs around 57% — then an agent will act confidently and wrongly, at machine speed, across your entire territory list. That is meaningfully worse than a dashboard being wrong, because a dashboard is read by someone who can disbelieve it.

Where should a pharma company start with AI agents?

Start where four conditions hold simultaneously: the task is reversible, so a mistake can be undone; it is auditable, so you can reconstruct what the agent did and why; it is administrative rather than clinical or promotional in its consequence; and the data it acts on is already good enough to trust. In practice that points to call reporting and administrative capture, content assembly from an approved library, meeting and inquiry handling, and internal document drafting. It points away from anything that contacts a physician or patient unsupervised, and away from anything reasoning about clinical presentation.

The pattern in that table is that reversibility does most of the work. An agent whose output a human reviews before it has consequence can be wrong without causing harm, which means you can deploy it, learn from it and improve it — the ordinary way capability gets built. An agent whose action is irreversible has to be right before deployment, which in practice means it does not get deployed. Organisations that start with reversible agents accumulate operating experience; organisations that start with the impressive irreversible ones accumulate steering committee slides.

Why agentic projects fail in pharma specifically

The general failure drivers apply — escalating cost without demonstrated value, inadequate governance, poor data quality, unclear metrics. Pharmaceutical organisations add four of their own: promotional content cannot be generated freely because it must clear medical, legal and regulatory review; the customer master is frequently unreliable in ways nobody has quantified; validation and change control expectations sit awkwardly with systems whose behaviour changes when a model is updated; and the field workforce has learned from a decade of system rollouts to expect more reporting rather than less.

The third row deserves particular attention from anyone in a regulated function. An agent is not a static system: its behaviour can change when the underlying model is updated, which is a different proposition from a validated application whose logic is fixed until someone changes it deliberately. That does not make agents unusable in regulated contexts — the FDA's own deployment is evidence enough of that — but it does mean version pinning and documented revalidation triggers need to be in the design rather than negotiated afterwards.

A 90-day plan for your first production agent

The objective of a first agent is not the value it delivers. It is to move your organisation from the 80% who have embedded one to the 31% who operate one, cheaply, in a way that builds the governance and the field trust that later deployments depend on.

1. Days 1–10: sort your candidate list into the three tiers. Take every agentic use case on your roadmap and classify it as shipped, piloted or described, using the date-name-geography test. Roadmaps built largely from tier three are common and are worth discovering now rather than in month six.
2. Days 11–20: apply the four filters. Reversible, auditable, administrative, and sitting on data you already trust. Most candidate use cases fail at least one. What survives is usually a shorter and less exciting list than the one you started with, and it is the list that will work.
3. Days 21–30: audit the data the agent will act on. Sample 200 records against reality. Given that 52% of enterprises name data quality as their primary blocker, this step decides more outcomes than the vendor choice does. If duplication is material, remediation becomes the project and the agent waits.
4. Days 31–40: decide accountability before capability. Who is answerable for an action the agent takes? What is the rollback procedure? What triggers revalidation when the model is updated? Write it down and have it approved. Only around a fifth of organisations have this, and its absence is what turns a pilot into a stalled pilot.
5. Days 41–50: capture the baseline. Whatever the agent is meant to improve — time, cycle length, error rate, cost per transaction — measure it before deployment. A baseline captured afterwards is not a baseline, and without one you will be arguing from impressions at the first review.
6. Days 51–70: deploy narrowly, with a human in the loop by design. One team, one workflow, one geography. The human review step is not a temporary safeguard to be removed later; it is what makes the deployment reversible and therefore deployable.
7. Days 71–80: instrument the override. Capture every instance where a human corrected or rejected the agent's output, with a reason. This is your improvement signal and your governance evidence, and systems built without it cannot be improved except by guessing.
8. Days 81–90: measure against the baseline and decide honestly. Expand, adjust or stop. Given that over 40% of agentic projects are forecast to be cancelled, a disciplined stop is a normal and respectable outcome — and much cheaper at ninety days than at eighteen months.

Treat steps three and four as gating. An agent acting on unreliable data will be confidently wrong at scale, and an agent whose accountability has not been settled will stall at the first incident — usually at exactly the point where expanding it would have started to pay.

What changes in India and emerging markets

Three things. The data quality constraint binds harder — discrepancy rates around 57% in pharma CRM doctor records make the top global blocker a bigger obstacle here than the aggregate suggests. The highest-value agents are different, because the field force is the primary channel and administrative burden is heavier, which favours reporting and enablement agents over digital orchestration. And the regulatory frame is DPDP and UCPMP 2024 rather than the frameworks most vendor governance material assumes.
 

The first row is not a footnote. Globally, data quality is the most-cited blocker at 52%; in Indian pharmaceutical commercial operations the underlying problem is measurably worse than the global average implies. That ordering — data before agents — is the least exciting recommendation in this article and the one most likely to determine whether an agentic programme produces value or a cancelled project. We cover the remediation in doctor data validation and enrichment.

Where Multiplier AI fits — and where it does not

This article covers the whole value chain and we operate in a narrow part of it. The boundary:

Do not shortlist us if

• You need an agentic platform. Veeva, Salesforce, IQVIA and Axtria ship agent platforms with catalogues, orchestration and governance tooling. We are not one of them and we integrate rather than compete.
• Your use case is research, clinical, manufacturing or regulatory. Everything outside commercial and medical affairs in the value-chain table is a different market with different specialists.
• You need next-best-action decisioning. That is Aktana under PharmaForceIQ, ZAIDYN, ODAIA, IQVIA or your CRM's native capability.
• You want agentic AI strategy consulting. Roadmap design, governance frameworks and operating model change are consulting engagements. BCG, McKinsey, ZS, Axtria and IQVIA do this work.

Do shortlist us if

• Your first project is the data, as the evidence suggests it should be. With 52% of enterprises naming data quality as the primary blocker and our audits showing around 57% discrepancy in pharma CRM doctor records, our GenAI Doctor Data Platform addresses the constraint before the agent does.
• Your agents will produce messages that need to be sent. A recommendation with no approved asset behind it is a notification. Our Hyper Personalized Content Platform assembles approved content by cohort and delivers it across email, WhatsApp and social.
• Execution must respect consent at the moment of sending. In markets where WhatsApp is the working channel and DPDP enforcement is approaching, this is where agentic output either becomes compliant action or stays a suggestion.
• You want measured commercial outcomes alongside the technology. Published outcomes from Indian deployments include a minimum 120% increase in time spent in the doctor's cabin, a 37% increase in medical representative efficiency and a 35% increase in brand share of voice with doctor influencers.

The mistakes that produce cancelled projects

• Building a roadmap from tier-three use cases. Apply the date-name-geography test to every item before it becomes a budget line.
• Starting with the irreversible use case. Ambition selects the impressive one. Reversibility should be a selection criterion, because it is what allows you to deploy, be wrong, and improve.
• Deploying agents onto unaudited data. An agent acts on what it believes; 52% of enterprises name data quality as their primary blocker, and in Indian commercial operations the underlying problem is worse than that average.
• Deferring accountability. Decide who is answerable for an agent's action and what the rollback is before deployment. Only around 21% of organisations have mature governance here, and its absence is what stalls pilots.
• Treating go-live as the outcome. Capture the baseline first, or the first serious review becomes a discussion about impressions.
• Removing the human review step to look more advanced. The review step is what makes the deployment reversible. Removing it converts a working system into an unapproved one.
• Ignoring the override signal. Every human correction is improvement data and governance evidence. Systems built without capturing it can only be improved by guessing.
• Assuming benchmark performance predicts operational behaviour. It does not, particularly on messy real-world data — which is what an agent will actually encounter.

Key takeaways

• Sort every claim into shipped, piloted or described using the date-name-geography test. Roadmaps built from tier three are common and expensive.
• Commercial has the deepest shipped tier in pharma — Veeva, Salesforce, IQVIA, Axtria, ZS — and is the function most independent surveys omit.
• The FDA announced agentic AI for all agency employees on 1 December 2025. A regulator using agents changes the credibility conversation in a regulated industry.
• Daiichi Sankyo with BCG is the clearest named pharma pilot: HCP and patient inquiry personalisation in Europe and Canada, extending to content and protocol writing.
• Outside commercial, manufacturing deviation investigation is the most production-like use case, with reported 40–50% cycle-time reductions.
• 80% of enterprise applications embed an agent; 31% of enterprises run one in production; over 40% of projects are forecast to be cancelled by end of 2027.
• The binding constraint is data, not models. 52% name data quality as the primary blocker, and only 21% report mature agent governance.
• Start where the task is reversible, auditable, administrative and sitting on data you trust. That combination is what separates the 31% from the 80%.

The gap between embedding and operating

The most useful statistic in this entire field is the distance between two numbers: roughly 80% of enterprise applications now contain an AI agent, and roughly 31% of enterprises run one in production. Nearly every pharmaceutical company already owns agentic capability, because their vendors added it. Far fewer have changed anything about how work gets done. The difference between those two states is not technology — it is data that can be trusted, governance that assigns accountability, a baseline that permits measurement, and a first use case chosen for reversibility rather than for how well it demonstrates.

That framing also explains why the shipped tier is deepest in commercial while the coverage is thinnest there. Commercial systems were already vendor-supplied, already integrated, and already full of tasks that are administrative, reviewable and previously proceduralised — which is the exact profile of work agents currently do well. Meanwhile the functions that generate the most excitement in this category are the ones where autonomy is least appropriate and the evidence is thinnest.

Sort your roadmap into three tiers. Audit the data before you buy the agent. Start with something you can undo. And measure it, because in a category where more than forty per cent of projects are forecast to be cancelled, being able to prove what happened is what keeps a programme alive long enough to matter.

Frequently Asked Questions For Agentic AI Use Cases Pharma